HealthTronics to Buy Endocare
HealthTronics announced that it has entered into a definitive merger agreement with Endocare.
Member Spotlight
Electro-Optical Submits MelaFind for Premarket Approval
Electro-Optical Sciences anounced that it has submitted a Premarket Approval Application to the U.S. Food and Drug Administration for MelaFind.
Sensimed Honored With Red Herring Award
Sensimed, a Swiss company focused on the development of integrated micro-systems for medical devices, has received the Red Herring 100 Europe 2009 Award.
SyntheMed’s REPEL-CV Approved by Australian Regulators
REPEL-CV, an anti-adhesion barrier developed by biomaterials company SyntheMed, has received approval by the Australian Therapeutic Goods Administration for use in open-heart surgery.
Biogen Idec, Electro-Optical Among “5 Stocks Approaching Greatness”
Investment website The Motley Fool has published a list of five stocks approaching greatness–and four of them are within the life sciences industry.
Clarient Stock Deal Frees Up Cash for Safeguard Scientifics
Safeguard Scientifics Inc. has received $19.5 million in cash, and freed up another $12.3 million in cash due to one of its portfolio companies completing the second part of a private placement of convertible preferred stock.
TargetScan Touch Proven Effective in Duke Study
A study published in Technology in Cancer Research and Treatment shows that Envisioneering Medical’s TargetScan Touch system is more effective in detecting prostate cancer than traditional biopsy methods.
TearLab Gets FDA 510(k) Approval
TearLab Corporation has received FDA 510(k) clearance of its TearLab Osmolarity System.
BioNeutral to Expand Into Asia
BioNeutral Group, a developer of chemical-based technology, announced that they will form a new wholly owned subsidiary in Hong Kong to commercialize their proprietary chemical formulations throughout Asia.
Bioject Signs With U.S. Navy for Malaria Vaccine
Bioject Medical Technologies, a developer of needle-free injection systems, has signed a cooperative R&D agreement with the U.S. Navy to use Bioject’s technology in a malaria vaccine the Navy is developing.